Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

Pancreatic cancer uses a sugar-coated disguise to evade the immune system, helping explain why it’s so hard to treat.

The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...

Researchers from DTU have patented an invention that uses naturally produced substances from gut bacteria of the bifidobacteria type to reduce the risk of allergies and asthma.

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio ...

Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.

Adimab's latest partner program to receive approval is GSK's Exdensur (depemokimab), approved in the US for the treatment of severe asthma with an eosinophilic phenotype and in the UK and Japan for ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...